A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
Trial details
- Registry ID
- NCT05933200
- Phase
- Phase 3
The FDA approved Triheptanoin (Dojolvi) on 30 Jun 2020.
Drug identity checked against registry records
Also recorded as Dojolvi; UX007
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODNCT05933200 | RARE | Phase 3 | Active not recruiting | 2027-08Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-06-30Day | Triheptanoin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213687", "applicant_as_listed_by_fda": "ULTRAGENYX PHARM INC", "brand_names": ["DOJOLVI"], "active_ingredients": ["TRIHEPTANOIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20200630", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |